Adverse reactions and treatment measures of mitapivat-Pyrukynd

Mitapivat - Pyrukynd is a drug indicated for the treatment of hemolytic anemia caused by pyruvate kinase (PK) deficiency in adults. As a pyruvate kinase activator, Metapival improves red blood cell function by activating pyruvate kinase (PK), thereby reducing red blood cell destruction. However, like other drugs, metapival also has some potential adverse reactions, and patients need to be regularly monitored and take appropriate treatment measures when using this drug.

In clinical research and application, the adverse reactions of metapival are relatively mild, but they still require attention. The most common adverse reactions include laboratory abnormalities, back pain, joint pain, and changes in estrogen levels. In the face of these adverse reactions, it is very important to take appropriate countermeasures. First, for laboratory abnormalities, doctors typically monitor urate and hormone levels regularly after a patient begins treatment. If these levels are found to be abnormal, doctors may adjust the medication dosage or use other treatments based on the patient's specific condition. For example, if uric acid levels rise significantly, uric acid-lowering drugs may need to be combined; if estrogen levels drop significantly, your doctor may evaluate the need for hormone replacement therapy.

Back pain and joint pain are usually treated symptomatically, such as pain relief with nonsteroidal anti-inflammatory drugs (NSAIDs) or physical therapy. For those with more severe symptoms, it may be necessary to consider suspending medications or adjusting treatment regimens.

When using Metapival, patients should always keep in close contact with their doctors and report any discomfort and abnormal symptoms in a timely manner so that the doctor can adjust the treatment plan or provide appropriate treatment measures as needed.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/pyrukynd